GA-STONEBRANCH
27.2.2024 19:25:26 CET | Business Wire | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, announced another year of significant growth and innovation. Building on the unprecedented success of 2022, Stonebranch has continued to expand its offerings with major product updates and a host of strategic integrations that solidify its position as a leader in the IT automation industry.
New Customer and Partner Relationships Fuel Growth
In 2023, Stonebranch significantly expanded its customer base, welcoming a diverse range of new clients from various sectors, including finance, healthcare, manufacturing, and technology. In addition, new technology, channel, and consulting partnerships enhanced Stonebranch’s capabilities and market reach.
Reflecting on the company's growth, Stonebranch CEO Giuseppe Damiani stated, "2023 was a pivotal year for Stonebranch. Our ability to attract and retain such a diverse clientele speaks volumes about our users' trust and confidence in our solutions. As organizations continue to navigate the complexities of digital transformation, Stonebranch continues to be a provider and partner of choice. It's inspiring to see such a wide array of organizations recognize the value of our solutions, and we’re excited to shape the future of IT automation with them.”
Universal Automation Center Elevates User Experience
Stonebranch introduced substantial enhancements to the Universal Automation Center (UAC) platform in 2023, focusing on elevating the user experience and broadening the scope of automation capabilities for IT Ops, DataOps, MLOps, and CloudOps professionals. Key highlights include the launch of:
- Observability with OpenTelemetry: UAC 7.5 introduced the OpenTelemetry connector, which makes telemetry data available via the OpenTelemetry standards. This feature collects log, metric, and trace data from UAC and third-party applications integrated with the UAC. Then, it outputs that collected data to application performance management (APM) tools (like Splunk, Dynatrace, and DataDog) and observability/business intelligence tools (like Grafana, Jaeger, and PowerBI).
- SAP Enhanced View: UAC has always made it easy for IT Ops teams to manage SAP tasks. With the release of UAC 7.5, Stonebranch extended this ease to business users too, by rolling out a new guided interface that’s intuitive for anyone who usually works with SAP ECC or S/4HANA.
- Jobs-as-Code: Building on UAC’s DevOps capabilities, jobs-as-code enables developers to manage jobs and workflow configuration just like business application code — directly from their integrated development environment (IDE) of choice. Additionally, by integrating UAC with source control repositories like GitHub, GitLab, and Azure DevOps, developers can establish continuous delivery pipelines that offer version control, testing capabilities, and CI/CD best practices.
- Strategic Integrations for a Connected Ecosystem: 2023 also marked the debut of several pivotal integrations, reinforcing Stonebranch's commitment to foster a more connected and agile IT ecosystem. New integrations include SAP IBP and SAP HANA XSA, DBT, Azure Synapse, SQL OBDC, Fivetran, Databricks, Temenos, Oracle EBS, Azure AZ CLI, Google Cloud Composer, and Red Hat OpenShift. These additions enhance UAC’s ability to seamlessly connect and orchestrate across diverse IT landscapes, driving unparalleled efficiency and innovation.
"Innovation is at the heart of everything we do at Stonebranch,” says Stonebranch CTO Peter Baljet. “Our commitment as a product leader is driven by our customers' rapidly evolving needs as they adopt new IT landscape paradigms. Looking ahead, we aim to enable businesses with the full potential of automation, transforming their operations and setting new levels for agility, observability, and scalability."
Accolades Celebrate Excellence at Stonebranch
Stonebranch is consistently recognized for its innovation, leadership, and workplace culture by prestigious organizations and industry analysts. These accolades highlight Stonebranch's commitment to providing cutting-edge automation solutions and fostering a supportive, dynamic work environment. Some of the notable recognition Stonebranch received in 2023 include:
- Gartner®: The research and consulting firm recognized Stonebranch in a variety of reports and guides in 2023, such as the Market Guide for Service Orchestration and Automation Platforms (SOAPs), Data and Analytics Essentials: DataOps Report, Hype Cycle for IT Infrastructure and Operations (I&O), and more.
- EMA: As a Value Leader in the 2023 EMA Radar™ Report for Workload Automation and Orchestration, Stonebranch was recognized as a “top-tier orchestrator capable of automation on-premises and in the cloud.”
- G2: In its reports for workload automation and managed file transfer, the peer-review platform awarded Stonebranch three Leader badges, a High-Performer badge, and an Easiest Doing Business With badge.
- Atlanta Journal-Constitution / Energage: Based solely on employee feedback, Stonebranch was recognized as a Metro Atlanta Top Workplace for the second consecutive year.
“These awards and recognitions are not just milestones but also motivation for us at Stonebranch,” noted Damiani. “As we celebrate these achievements, we remain focused on pushing the boundaries of what's possible in IT automation and orchestration.”
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using the Stonebranch Universal Automation Platform, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227593444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom